Abstract: An extension cannula and in-line connector for use with a conventional ECMO return cannula is provided. The extension cannula includes a self-expanding conduit transitionable between a collapsed insertion state and an expanded, deployed state via a retractable sheath. The extension cannula may be inserted through a conventional ECMO return cannula such that the proximal end of the self-expanding conduit is disposed within and proximal to the end of the conventional ECMO cannula, while the distal end of the self-expanding conduit is disposed in a patient's thoracic aorta to improve cerebral oxygenation, maintain systemic arterial pulsatility, and reduce the potential for end-organ injury. The extension cannula and/or in-line connector may be used to permit delivery of additional interventional or vascular equipment using a single port of access, thereby avoiding complications associated with contemporary VA-ECMO.

Abstract: An implant sized and shaped to be endovascularly delivered to the middle meningeal artery includes a carrier that carries a payload between first and second ends thereof. An anchor mechanism associated with the implant transitions into a swollen state in response to exposure to bodily fluids. In the swollen state, said anchor mechanism anchors the implant to the middle meningeal artery. Before or during the transition, the anchor mechanism permits endovascular delivery of the implant to the middle meningeal artery.

Abstract: Implantable shunt devices and methods for draining cerebrospinal fluid from a patient's subarachnoid space include a shunt having opposed first and second ends, the second end being constructed to penetrate a wall of a sigmoid, transverse, straight, or sagittal sinus of the patient, a one-way valve, a hollow passageway extending between the second end and the one-way valve such that cerebrospinal fluid can be drained through the second end and out through the valve, and a mechanism coupled to the shunt and configured to anchor the shunt at a desired location proximal to the subarachnoid space.

Abstract: The present application provides methods for preparing soluble lipidated ligand agents comprising a ligand entity and a lipid entity, and in some embodiments, provides relevant parameters of each of these components, thereby enabling appropriate selection of components to assemble active agents for any given target of interest.

Abstract: The present disclosure relates to, among other things, compositions and methods for treating an inflammatory condition including, but not limited to, ocular inflammation, dry eye disease, and ocular neuropathic pain. One aspect of the present disclosure relates to a composition comprising (a) chemerin or a fragment or analog thereof and (b) a lipid entity linked to the chemerin or fragment or analog thereof.

Abstract: An extension cannula and in-line connector for use with a conventional ECMO return cannula is provided. The extension cannula includes a self-expanding conduit transitionable between a collapsed insertion state and an expanded, deployed state via a retractable sheath. The extension cannula may be inserted through a conventional ECMO return cannula such that the proximal end of the self-expanding conduit is disposed within and proximal to the end of the conventional ECMO cannula, while the distal end of the self-expanding conduit is disposed in a patient's thoracic aorta to improve cerebral oxygenation, maintain systemic arterial pulsatility, and reduce the potential for end-organ injury. The extension cannula and/or in-line connector may be used to permit delivery of additional interventional or vascular equipment using a single port of access, thereby avoiding complications associated with contemporary VA-ECMO.

Abstract: Methods and compositions for preventing and/or treating diseases and conditions caused by certain apicomplexan infections are provided. The methods involve administering/providing to a subject one or more of tartrolon D and E, including isomers thereof. Exemplary apicomplexan infections that are prevented/treated by the compounds of the invention include those caused by Cryptosporidium, Babesia, Cyclospora, Isospora, Plasmodium, Sarcocystis, Besnoitia, Hammondia, Neospora, Theileria and Toxoplasma.

Abstract: Provided herein are compositions and methods for treating or preventing metabolic disorders. In particular, provided herein are compositions, methods, and uses of Cyclin-dependent Kinase 6 (CDK6) inhibitors for treating and preventing metabolic diseases (e.g., type II diabetes, obesity, metabolic syndrome, elevated blood pressure, cardiovascular diseases, elevated fasting plasma glucose, and high serum triglycerides).

Abstract: Systems and methods and devices are provided for treating conditions such as heart failure and/or pulmonary hypertension by at least partially occluding flow through the superior vena cava for an interval spanning multiple cardiac cycles. A catheter with an occlusion device is provided along with a controller that actuates a drive mechanism to provide at least partial occlusion of the patients superior vena cava, which reduces cardiac filling pressures, and induces a favorable shift in the patients Frank-Starling curve towards healthy heart functionality and improved cardiac performance. The occlusion device may include a lumen obstructed by a relief valve that may permit fluid flow through the occlusion device to release an excessive build-up of pressure.

Abstract: Disclosed are implementations, including a method for video presentation to cause controllable stimulation of a subject's eyes, that includes preparing a video presentation comprising successive frames of moving images, and, for one or more of the successive frames, selecting a target feature(s) represented in the moving images, with the moving images further comprising one or more background features, the target feature causing stimulation of one of a first eye or a second eye of the subject. For at least some of the frames in which the target feature(s) appears, the method also includes controlling a first contrast characteristic of the target feature(s) to form a first portion of the moving images, and controlling a second contrast characteristic of the one or more background features to form a second portion of the moving images. The method further includes providing the prepared video presentation.

Abstract: Systems and methods and devices are provided for treating conditions such as heart failure and/or pulmonary hypertension by at least partially occluding flow through the superior vena cava for an interval spanning multiple cardiac cycles. A catheter with an occlusion device is provided along with a controller that actuates a drive mechanism to provide at least partial occlusion of the patient's superior vena cava, which reduces cardiac filling pressures, and induces a favorable shift in the patient's Frank-Starling curve towards healthy heart functionality and improved cardiac performance. The occlusion device may include a lumen obstructed by a relief valve that may permit fluid flow through the occlusion device to release an excessive build-up of pressure.

Abstract: Systems and methods are provided for treating conditions such as heart failure and/or pulmonary hypertension by at least partially occluding flow through the superior vena cava for an interval spanning multiple cardiac cycles. A catheter with an occlusion device is provided along with a controller that actuates a drive mechanism to provide at least partial occlusion of the patient's superior vena cava, which reduces cardiac filling pressures, and induces a favorable shift in the patient's Frank-Starling curve towards healthy heart functionality and improved cardiac performance. The system may include sensors to determine the degree of occlusion of the superior vena cava. The occlusion system may be used to reduce volume in a heart and facilitate a cardiac procedure. The occlusion system may be used to relieve an overloaded chamber during and/or after deploying a VAD.

Abstract: The present disclosure relates to derivatized agelastatin compounds and methods for the treatment, prevention, or delay of cancer, comprising administering a therapeutically effect amount of the derivatized agelastatin compounds, a pharmaceutically acceptable salt thereof, or a composition thereof to a subject in need thereof. Methods for making the derivatized agelastatin compounds are also provided.

Abstract: Disclosed are devices, electrodes, systems, methods, and other implementations, including a device that includes an electrode comprising an elongated body, a plurality of electrode contacts disposed on a first side of the elongated body, and a cannulation channel defined along a longitudinal axis of the electrode. The device further includes a guiding mechanism received within the cannulation channel, the guiding mechanism configured to guide the electrode for placement at a target area inside a body of a patient. In some embodiments, the cannulation channel is configured to receive irrigation fluids dispensed through a perforated end located near a leading tip of the elongated body.

Abstract: Disclosed here is the rational design and use of potent and specific GPCR antagonist pepducins based on GPCR regions such as the third intracellular loop and adjacent regions.

Abstract: The present disclosure relates to, among other things, compounds and methods for treating neuropathic pain, ocular pain, ocular inflammation, and/or dry eye and methods of detecting mutations in specific G-protein coupled receptors, such as missense mutations, and determining the extent to which these mutations alter the pharmacological response of the G-protein coupled receptor.

Abstract: A purpose-made predictive instrument for the administration of cardiac metabolic support for acute coronary syndromes (ACS, which include unstable angina and acute myocardial infarction) that particularly identifies those most likely to benefit from treatment. In some examples, such a predictive instrument is used for real-time decision support for the administration of treatments such as glucoseinsulin-potassium (GIK).

Abstract: Systems and methods and devices are provided for arresting or reversing the effects of myocardial remodeling and degeneration after cardiac injury, without the potential drawbacks associated with previously existing systems and methods, by at least partially occluding flow through the superior vena cava over multiple cardiac cycles, and more preferably, by adjusting the interval or degree of occlusion responsive to a sensed level of patient activity. In some embodiments, a controller is provided that actuates a drive mechanism responsive to a sensed level of patient activity to provide at least partial occlusion of the patient's superior vena cava, while a data transfer circuit of the controller provides bi-directional transfer of physiologic data to the patient's smartphone or tablet to permit display and review of such data.

Abstract: Systems and methods and devices are provided for treating conditions such as heart failure and/or pulmonary hypertension by at least partially occluding flow through the superior vena cava for an interval spanning multiple cardiac cycles. A catheter with an occlusion device is provided along with a controller that actuates a drive mechanism to provide at least partial occlusion of the patient's superior vena cava, which reduces cardiac filling pressures, and induces a favorable shift in the patient's Frank-Starling curve towards healthy heart functionality and improved cardiac performance. The occlusion device may include a lumen obstructed by a relief valve that may permit fluid flow through the occlusion device to release an excessive build-up of pressure.

Abstract: The present invention relates to methods of treatment of light chain amyloidosis and other CD38-positive hematological malignancies with anti-CD38 antibodies.